| Price and Volume | |
|---|---|
| Recent Price | 1.39 |
| 52 Week High | 2.46 |
| 52 Week Low | 1.00 |
| Avg. Daily Vol. (Mil) | 0.06 |
| Beta (3 year) | 1.03 |
| Share Related Items | |
| Mkt Cap (Mil) | 57.24 |
| Shares Out (Mil) | 41.18 |
| Float (Mil) | 0.00 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.50 |
| Current Ratio | 4.70 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.00 |
| Price/Book | 5.56 |
| Price/Cash Flow | -3.70 |
| Per Share Data | |
| Earnings | -0.40 |
| Sales | 0.00 |
| Book Value | 0.25 |
| Cash Flow | -0.38 |
| Business Summary | |
|---|---|
| A development stage Company, which focuses on research and development efforts on the development of REOLYSIN (r) , its potential cancer therapeutic. | |
| General Information | |
| 1167 Kensington Crescent NW
Suite 210 Calgary, Alberta, T2N 1X7 |
|
| www.oncolyticsbiotech.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 9 | |
| CEO: Dr. Bradley G. Thompson, | |
| Short Interest | |
| Current Month (Mil) | 0.00 |
| Previous Month (Mil) | 0.00 |
| Short Interest Ratio (Days) | 0.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -128.90 |
| Return on Investments | -162.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |